To the Editor:

Patients with diabetes mellitus are susceptible to active tuberculosis (TB) and latent TB infection (LTBI) \[[@C1]--[@C3]\]. Close contact with patients with infectious TB is associated with an increased risk of having coprevalent TB or developing incident TB \[[@C4], [@C5]\]. However, information on the burden of incident TB in contacts with underlying diabetes is limited. Considering post-exposure TB in patients with diabetes, metformin has demonstrated anti-TB effects in preclinical studies and association with a low LTBI prevalence in a cross-sectional survey \[[@C6], [@C7]\]. Despite metformin\'s wide use and correlation with a lower TB risk in patients with type 2 diabetes (T2D) \[[@C8]\], the impact of metformin use during TB exposure on subsequent TB risk has not been thoroughly investigated. We aimed to obtain the rate of post-exposure incident TB, but not coprevalent TB, in T2D patients and evaluate whether TB risk can be modified by metformin use during the TB-exposure period.

This retrospective cohort study in TB contacts used the National Health Insurance Research Database (with approval from Taipei City Hospital: TCHIRB-10704109-W), in a manner as previously used by Y[en]{.smallcaps} *et al*. \[[@C9]\]. This database includes longitudinal claims data of \>23 million beneficiaries in Taiwan and has contributed to numerous validated reports \[[@C4], [@C8]\]. We identified TB contacts by diagnostic International Classification of Diseases, ninth revision, clinical modification (ICD-9-CM) code of V01.1 plus chest radiography orders in outpatient records from 2008 to 2014, when TB-contact investigation is mandatory in Taiwan \[[@C4]\]. The index date was the date of coding of V01.1. To minimise confounding variables, we excluded subjects with a prior TB history, preventive therapy for LTBI, type 1 diabetes and those with chronic kidney disease, in who metformin is contradicted \[[@C8]\].

We defined T2D patients by the presence of 250.x0 and 250.x2 ICD-9 codes (one inpatient or more than three outpatient records in the 6 months before and after the index date) \[[@C8]\]. Using the defined daily dose (DDD) of metformin \[[@C8]\], *i.e.* 2000 mg, we defined a T2D subject as having metformin use during TB exposure (T2D-useMet) if the cumulative DDD of metformin was \>30 within 6 months before the index date; the others were T2D without metformin (T2D-nonMet). The outcome, after excluding subjects with coprevalent TB occurring within 6 months, was post-exposure incident TB developing after the initial 6 months \[[@C5]\]. We identified TB by codes 010--018 plus prescription of anti-TB drugs in all subjects until December 2016, death or 3 years \[[@C8]\]. We recorded potential confounders including diabetes severity as indicated by the adapted diabetes complication severity index (aDCSI) score ([table 1](#TB1){ref-type="table"}) \[[@C8]\]. We used SAS (version 9.4; SAS Institute, Cary, NC, USA) for data extraction and analysis, and Cox regression analysis to assess predictors for incident TB.

###### 

Demographic data of the whole cohort and analysis of the risk factors for post-exposure incident tuberculosis (TB) in patients with type 2 diabetes (T2D)

  **Variables**                    **TB contact cohort**   **Nondiabetes participants**   **T2D participants**   **Cox analysis of risk factors for TB in T2D population**                                                      
  ------------------------------- ----------------------- ------------------------------ ---------------------- ----------------------------------------------------------- ------------------- ----------- ------------------- -----------
  **Subjects n**                          205 797                    185 189                      9851                                    10 757                                                                                
  **Age years**                         46.24±15.17                44.90±14.44                59.10±16.74                               57.49±15.70                          1.01 (1.00--1.02)  0.088        1.00 (0.99--1.02)  0.455
  **Male sex**                       106 301 (51.65%)            94 523 (51.04%)             5719 (58.06%)                             6059 (56.33%)                         1.70 (1.19--2.43)  0.004        1.71 (1.18--2.47)  0.005
  **Income level**                                                                                                                                                                                                              
   Low                                39 865 (19.37%)            34 088 (18.41%)             2970 (30.15%)                             2807 (26.09%)                               1.00                            1.00         
   Intermediate                      112 053 (54.45%)            101 464 (54.79%)            4832 (49.05%)                             5757 (53.52%)                         0.84 (0.58--1.22)  0.372        1.01 (0.68--1.51)  0.942
   High                               53 879 (26.18%)            49 637 (26.80%)             2049 (20.80%)                             2193 (20.39%)                         0.69 (0.42--1.13)  0.141        0.89 (0.52--1.52)  0.669
  **Urbanisation**                                                                                                                                                                                                              
   Urban                             114 124 (55.45%)            103 798 (56.05%)            4951 (50.26%)                             5375 (49.97%)                               1.00                            1.00         
   Suburban                           70 748 (34.38%)            63 307 (34.19%)             3529 (35.82%)                             3912 (36.37%)                         1.16 (0.80--1.69)  0.441        1.11 (0.75--1.63)  0.601
   Rural                              20 925 (10.17%)             18 084 (9.77%)             1371 (13.92%)                             1470 (13.67%)                         1.99 (1.30--3.06)  0.002        1.83 (1.17--2.88)  0.008
  **Comorbidities**                                                                                                                                                                                                             
   COPD or asthma                     24 763 (12.03%)            19 316 (10.43%)             3039 (30.85%)                             2408 (22.39%)                         1.49 (1.05--2.12)  0.027        1.24 (0.85--1.80)  0.261
   Malignancy                          6712 (3.26%)                5080 (2.74%)               869 (8.82%)                               763 (7.09%)                          1.19 (0.66--2.15)  0.565        1.03 (0.57--1.89)  0.913
   Liver cirrhosis                     1966 (0.96%)                1281 (0.69%)               396 (4.02%)                               289 (2.69%)                          2.81 (1.52--5.20)  0.001        2.00 (1.02--3.92)  0.042
   Alcoholism                          1498 (0.73%)                1151 (0.62%)               214 (2.17%)                               133 (1.24%)                          3.24 (1.52--6.94)  0.002        1.94 (0.84--4.47)  0.119
   Autoimmune disease                  5508 (2.68%)                4450 (2.40%)               532 (5.40%)                               526 (4.89%)                          0.80 (0.35--1.81)  0.594^\#^    0.72 (0.32--1.65)  0.440^\#^
   AIDS^\#^                                 234                    164 (0.09%)                 8 (0.08%)                                     4                                                                                  
   Organ Transplant^\#^                 48 (0.03%)                  10 (0.10%)                                                                                                                                                  
  **Steroid use^¶^**                   1408 (0.68%)                1093 (0.59%)               172 (1.75%)                               143 (1.33%)                          2.25 (0.83--6.09)  0.110        1.88 (0.69--5.12)  0.220
  **Statin use^¶^**                    9653 (4.69%)                4256 (2.30%)              1639 (16.64%)                             3758 (34.94%)                         0.66 (0.44--1.00)  0.049        0.77 (0.51--1.18)  0.236
  **Insulin use^¶^**                   1747 (0.85%)                 5 (0.00%)                 808 (8.20%)                               934 (8.68%)                          1.16 (0.66--2.05)  0.612        1.11 (0.62--2.00)  0.723
  **aDCSI score**                        0.64±1.24                  0.46±0.96                  2.27±2.04                                 2.30±1.96                           1.06 (0.98--1.15)  0.153        1.03 (0.94--1.12)  0.542
  **Follow-up duration years**           2.93±0.35                  2.94±0.30                  2.71±0.68                                 2.83±0.51                                                                              
  **Incident TB events**                912 (0.44%)                771 (0.42%)                 82 (0.83%)                               59 (0.55%)                                                                              
  **T2D status on TB exposure**                                                                                                                                                                                                 
   T2D non-metformin                   9851 (4.78%)                                                                                                                                1.00                            1.00         
   T2D metformin use                  10 757 (5.22%)                                                                                                                         0.63 (0.45--0.88)  0.007        0.69 (0.49--0.98)  0.036

Data are presented as n (%) or mean±[sd]{.smallcaps}, unless otherwise stated. HR: hazard ratio; aDCSI: adapted diabetes complication severity index. ^\#^: because the numbers of AIDS and organ transplant patients were too small to be publicly disclosed in the table, the two factors were combined into autoimmune disease for the univariate and multivariate Cox regression analyses. ^¶^: use of a comedication during TB exposure period is defined as taking a drug for \>30 cumulative defined daily doses within 6 months before the index date.

We identified 234 373 adult TB contacts aged \>20 years during 2008--2014. We excluded 3308 (1.4%) participants with prior TB, 1414 (0.6%) with coprevalent TB within 6 months after the index dates and 6161 (2.6%) receiving isoniazid preventive therapy for LTBI. After excluding subjects with chronic kidney disease and/or type 1 diabetes (n=5172) and T2D developed during 3-year follow-up (n=12 521), we finally included 205 797 participants for the analysis: 185 189 (90%) nondiabetes, 9851 (4.8%) T2D-nonMet and 10 757 (5.2%) T2D-useMet subjects. Compared with the nondiabetes group, the T2D groups were older and had more comorbidities and comedications, including statins. After a mean±[sd]{.smallcaps} follow-up of 2.93±0.35 years, we observed 912 (0.44%) incident TB events: 771 (0.42%), 82 (0.83%) and 59 (0.55%) in the nondiabetes, T2D-nonMet and T2D-useMet groups (p\<0.001), respectively. The corresponding incidences of TB were 1.4, 3.1 and 1.9 cases per 1000 person-years in the three groups ([table 1](#TB1){ref-type="table"}). The Kaplan--Meier curves of probabilities of incident TB after the initial post-exposure 6 months for the three groups were significant different (log-rank p\<0.001).

In the T2D population, metformin use during TB exposure significantly predicted incident TB in univariate analysis (p=0.007). Notably, T2D-useMet was negatively associated with TB after adjustment by cofactors with univariate p\<0.05 (adjusted hazard ratio (aHR) 0.69, 95% CI 0.49--0.98; p=0.037). In the fully adjusted model, T2D-useMet remained correlated with lower risk for TB development (aHR 0.69, 95% CI 0.49--0.98; p=0.036) ([table 1](#TB1){ref-type="table"}). Furthermore, compared with T2D-nonMet subjects, T2D-useMet subjects receiving a high dose of metformin had further declined risks of TB: aHR 0.87 (95% CI 0.56--1.37, p=0.558) in the subgroup receiving 30--90 DDD and 0.59 (95% CI 0.39--0.90, p=0.013) in that taking \>90 DDD within 6 months before the index date. While incorporating nondiabetes data into the analysis, we found that TB risk was highest in the T2D-nonMet group (aHR 1.41, 95% CI 1.01--1.97; p=0.045), followed by the nondiabetes (aHR 1.15, 95% CI 0.86--1.52; p=0.342), and was lowest in T2D-useMet (reference) groups after adjusting for age, sex, income, residence, all comorbidities, steroid and insulin use (all factors with univariate p\<0.05 in the whole-population analysis; statins not included due to p=0.917 in the univariate analysis).

In summary, our diabetes subjects with metformin use during TB exposure had a 31% lower risk of incident TB than those without and a similar risk to the controls without diabetes. In another TB contact study (5846 matched trios), L[ee]{.smallcaps} *et al.* \[[@C10]\] reported that, compared with diabetes without metformin, TB risk was 27% lower in matched metformin users taking ≥90 DDD within 1 year (aHR 0.73) and lowest in healthy contacts without any comorbidities (aHR 0.42). We think that their overtly healthy controls and accounting for coprevalent TB as the outcome may explain the deviation in their results from ours. Our study excluded coprevalent TB and found only 0.44% of contacts developed incident TB within 3 years. This finding is consistent with the result of the Amsterdam study: 0.39% incident TB events within 5 years \[[@C3]\]. Importantly, we present a dose--response association between metformin and incident TB. Our robust result suggests that metformin may modify the risk of TB disease in patients with diabetes who have been exposed to TB patients \[[@C7]\].

Regarding limitations, we lacked data on smoking, exposure types or LTBI status of the contacts and the sputum smear status of the index cases \[[@C5]\]. Second, because metformin might be used before TB exposure throughout the following years, whether metformin acts to prevent initial infection or reactivation from LTBI remains unknown.

In conclusion, we found, in patients with diabetes taking metformin, a decreased risk of post-exposure incident TB, in a low level similar to that in subjects without diabetes. These results may provide rationales for researching metformin\'s potential in preventive therapy after TB exposure.
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